3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
69
Carcinoma, Intraductal, Noninfiltrating
9
Breast Carcinoma In Situ
6
Breast Neoplasms, Male
5
Neoplasms
3
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Inflammatory Breast Neoplasms
2
Sleep Wake Disorders
1
Risk Reduction Behavior
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Obesity
1
Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer
1
Mastodynia
1
Glioma
1
Fibrocystic Breast Disease
1
Fibroadenoma
1
Fatigue
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Desmoid Tumors
1
Cystic Fibrosis
1
Cystadenocarcinoma, Serous
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Lobular
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Cancer Metastatic
1
Interventions
vandetanib
7
Sorafenib
6
Magnetic Resonance Spectroscopy
6
lenvatinib
5
cabozantinib
5
Sunitinib
4
Iodine-131
4
selpercatinib
3
AZD 6244
3
trametinib
2
tipifarnib
2
durvalumab
2
dabrafenib
2
alectinib
2
Triiodothyronine
2
Thyroxine
2
Thyrotropin Alfa
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Everolimus
2
Bortezomib
2
Axitinib
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
tremelimumab
1
temsirolimus
1
tanespimycin
1
sapanisertib
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Thyroid Neoplasms
×
Tamoxifen
×
Clear all
No trials found.